|
|
News Breaks | | | | September 20, 2012 | | 08:22 EDT |  | BVTI, ABPI | Biovest Int'l conducts meeting with EMA advancing EU approval for cancer vaccine
Biovest International (BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, (ABPI), conducted a regulatory meeting with the European Medicines Agency in London, at which the EMA provided Biovest with information to help finalize Biovest’s pending Marketing Authorization Application seeking EU marketing approval for BiovaxID, Biovest’s personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma. The meeting addressed legal, regulatory, and scientific matters for the planned MAA in order to facilitate subsequent validation and assessment of the application. The company anticipates the filing of the MAA for early next year. Upon approval, BiovaxID would be the first cancer vaccine available in Europe for lymphoma patients. | |
|
News For BVTI;ABPI From The Last 14 Days Check below for free stories on BVTI;ABPI the last two weeks. |
|
|
| There are no results for BVTI;ABPI |
|
|
|
|
|
|
